These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1216856)

  • 41. [L-dopa treatment in parkinsonism. Biochemical basis (author's transl)].
    Bieniowa A; Kolasa M; Reichowa J
    Przegl Lek; 1976; 33(4):463-7. PubMed ID: 1273343
    [No Abstract]   [Full Text] [Related]  

  • 42. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The clinical features of Parkinson's disease in 100 histologically proven cases.
    Hughes AJ; Daniel SE; Lees AJ
    Adv Neurol; 1993; 60():595-9. PubMed ID: 8420197
    [No Abstract]   [Full Text] [Related]  

  • 45. A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.
    De Michele G; Mengano A; Filla A; Trombetta L; Campanella G
    Acta Neurol (Napoli); 1989 Dec; 11(6):408-14. PubMed ID: 2694799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Crises in the course of Parkinson's disease].
    Danielczyk W
    Wien Med Wochenschr; 1980 Feb; 130(4):149-51. PubMed ID: 7376682
    [No Abstract]   [Full Text] [Related]  

  • 50. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].
    Morselli PL; Rizzo M; Tognoni G
    Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589
    [No Abstract]   [Full Text] [Related]  

  • 51. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Which risk factors predict the levodopa response in fluctuating Parkinson's disease?
    Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; Korten JJ; van 't Hof MA
    Ann Neurol; 1990 May; 27(5):537-43. PubMed ID: 2360795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
    Cohen G
    J Neural Transm Suppl; 1983; 19():89-103. PubMed ID: 6321651
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversible spastic and pyramidal tract signs in a patient with Parkinson's disease on L-dopa.
    Seyfert S; Straschill M
    J Neurol; 1977 Oct; 216(3):223-6. PubMed ID: 72141
    [No Abstract]   [Full Text] [Related]  

  • 55. [L-dopa + peripheral decarboxylase antagonist].
    Wiesel FA
    Lakartidningen; 1975 Oct; 72(43):4173. PubMed ID: 1177632
    [No Abstract]   [Full Text] [Related]  

  • 56. Current status of levodopa therapy in idiopathic Parkinson's disease.
    Gauthier S; Gauthier L
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):452-4. PubMed ID: 3676919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mortality of patients with Parkinson's disease treated with levodopa.
    Marttila RJ; Rinne UK; Siirtola T; Sonninen V
    J Neurol; 1977 Oct; 216(3):147-53. PubMed ID: 72132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    J Maine Med Assoc; 1977 Apr; 68(4):134-41, 146. PubMed ID: 845500
    [No Abstract]   [Full Text] [Related]  

  • 59. Variation of therapeutic response in Parkinson's disease: a retrospective study.
    Geminiani G; Cesana BM; Scigliano G; Soliveri P; Girotti F; Giovannini P; Caraceni T
    Acta Neurol Scand; 1990 May; 81(5):397-401. PubMed ID: 2375240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of afobazole and levodopa on the activity of proline-specific proteinases and adenosine deaminase in blood serum and brain structures of rats with experimental Parkinson's syndrome induced by systemic administration of rotenone].
    Ivanova EA; Zolotov NN; Kapitsa IG; Pozdnev VF; Valdman EA; Voronina TA
    Biomed Khim; 2017 Nov; 63(6):565-569. PubMed ID: 29251620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.